Last 20 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 9.84 | 8.00 | 10.80 | 11.04 | 10.94 | 18.27 | 26.32 | 6.27 | 6.91 | 81.25 | — | 11.90 | 10.05 | — | 21.25 | 13.09 | — | 13.89 | 14.02 | 17.36 | 17.25 |
| — | -56.2% | -59.0% | +76.1% | +58.4% | -77.5% | — | -47.3% | -31.3% | — | — | -9.1% | — | — | +51.6% | -24.6% | — | — | — | — | — | |
| P/S Ratio | 3.29 | 3.07 | 3.86 | 3.10 | 3.13 | 2.48 | 1.51 | 1.11 | 1.33 | 1.06 | 1.82 | 2.62 | 1.85 | 2.93 | 3.08 | 2.33 | 3.07 | 2.37 | 2.92 | 3.37 | 2.72 |
| — | +24.0% | +155.6% | +179.9% | +135.3% | +133.5% | -17.0% | -57.6% | -28.0% | -63.8% | -40.9% | +12.0% | -39.7% | +23.8% | +5.3% | -30.8% | +12.9% | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | 297.34 | — | — | 29.03 | 32.82 | 57.89 | 9.68 | 11.21 | 12.04 | 11.94 |
| — | — | — | — | — | — | — | — | — | — | — | +806.0% | — | — | +159.0% | +172.5% | +384.9% | — | — | — | — | |
| P/FCF | 146.02 | 13.17 | 5.96 | — | — | — | 3.26 | 4.21 | — | — | 6.47 | — | — | 41.53 | — | — | — | 9.51 | 24.27 | — | 3.83 |
| — | — | +83.1% | — | — | — | -49.7% | — | — | — | — | — | — | +336.5% | — | — | — | — | — | — | — | |
| EV / EBITDA | 7.64 | 6.28 | 8.56 | 7.56 | 9.14 | 7.26 | 5.45 | 4.14 | 4.08 | 27.04 | — | 9.38 | 7.62 | — | 11.51 | 8.15 | — | 6.66 | 7.27 | 9.33 | 8.20 |
| — | -13.6% | +57.0% | +82.6% | +124.0% | -73.1% | — | -55.8% | -46.5% | — | — | +15.1% | — | — | +58.4% | -12.6% | — | — | — | — | — | |
| EV / EBIT | 17.67 | 6.21 | 8.61 | 8.74 | 13.34 | 15.41 | 5.45 | 4.14 | 4.08 | 36.06 | — | 9.15 | 7.62 | — | 10.72 | 7.55 | — | 6.66 | 7.71 | 10.19 | 8.74 |
| — | -59.7% | +58.0% | +111.0% | +226.9% | -57.3% | — | -54.7% | -46.5% | — | — | +21.2% | — | — | +38.9% | -25.9% | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.1% | 85.7% | 85.7% | 87.4% | 82.1% | 80.3% | 82.8% | 83.5% | 92.3% | 77.5% | 73.6% | 86.6% | 82.6% | 83.0% | 81.9% | 84.6% | 81.8% | 82.8% | 82.8% | 82.1% | 82.5% |
| — | +6.8% | +3.5% | +4.7% | -11.0% | +3.5% | +12.5% | -3.6% | +11.8% | -6.6% | -10.1% | +2.4% | +0.9% | +0.3% | -1.1% | +3.0% | -0.8% | — | — | — | — | |
| Operating Margin | 21.4% | 50.8% | 46.6% | 43.2% | 34.1% | 31.5% | 23.8% | 24.8% | 32.1% | 1.3% | -39.5% | 26.4% | 20.8% | -67.5% | 22.1% | 22.5% | -106.6% | 24.1% | 28.5% | 26.1% | 20.2% |
| — | +61.3% | +95.7% | +74.2% | +6.1% | +2319.9% | +160.4% | -6.0% | +54.2% | +101.9% | -278.6% | +17.2% | +119.5% | -379.8% | -22.5% | -13.6% | -628.3% | — | — | — | — | |
| Net Margin | 16.9% | 38.5% | 35.6% | 28.1% | 28.5% | 13.4% | 6.0% | 17.7% | 19.7% | 1.3% | -32.4% | 21.5% | 18.4% | -49.8% | 14.1% | 17.4% | -75.6% | 17.7% | 21.7% | 19.8% | 16.1% |
| — | +187.7% | +496.8% | +58.9% | +44.4% | +926.6% | +118.4% | -17.7% | +7.1% | +102.6% | -329.6% | +23.5% | +124.4% | -381.9% | -34.9% | -12.2% | -568.4% | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | 610.5% | — | -290.3% | 41.3% | 71.4% | -131.5% | 17.9% | 20.8% | 18.9% | 17.7% |
| — | — | — | — | — | — | — | — | — | — | — | +755.2% | — | -1719.8% | +98.8% | +278.7% | -841.7% | — | — | — | — | |
| ROA | 16.6% | 10.7% | 10.0% | 7.4% | 7.8% | 2.9% | 1.3% | 3.5% | 4.2% | 0.3% | -6.5% | 3.8% | 3.0% | -7.5% | 2.2% | 2.5% | -10.6% | 2.4% | 2.8% | 2.3% | 2.0% |
| — | +264.7% | +688.5% | +112.5% | +83.6% | +998.2% | +119.6% | -8.0% | +42.0% | +103.5% | -390.3% | +52.3% | +128.1% | -412.0% | -19.6% | +8.0% | -639.9% | — | — | — | — | |
| ROIC | 342.7% | 126.3% | 89.2% | 82.9% | 157.8% | — | — | — | — | — | — | 137.3% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | 27.90 | — | — | 2.40 | 3.88 | 5.40 | 1.22 | 1.22 | 1.22 | 1.41 |
| — | — | — | — | — | — | — | — | — | — | — | +620.0% | — | — | +97.3% | +218.8% | +283.4% | — | — | — | — | |
| Debt / EBITDA | 1.23 | 2.75 | 3.12 | 3.61 | 2.76 | 3.42 | 4.75 | 5.21 | 3.71 | 23.67 | — | 3.48 | 4.04 | — | 4.19 | 4.43 | — | 4.45 | 4.07 | 4.78 | 5.84 |
| — | -19.6% | -34.3% | -30.7% | -25.6% | -85.5% | — | +49.5% | -8.2% | — | — | -21.3% | — | — | +3.1% | -7.3% | — | — | — | — | — | |
| Current Ratio | 0.71 | 0.61 | 0.84 | 0.86 | 0.71 | 0.96 | 0.90 | 0.88 | 0.89 | 0.83 | 0.85 | 0.92 | 0.98 | 0.98 | 1.13 | 1.08 | 1.24 | 1.70 | 1.70 | 1.73 | 1.80 |
| — | -35.6% | -7.3% | -2.5% | -20.2% | +15.0% | +5.5% | -5.0% | -9.0% | -15.7% | -24.1% | -14.1% | -20.6% | -42.0% | -33.9% | -38.0% | -31.2% | — | — | — | — | |
| Quick Ratio | 0.55 | 0.50 | 0.66 | 0.66 | 0.55 | 0.79 | 0.76 | 0.72 | 0.70 | 0.65 | 0.68 | 0.74 | 0.88 | 0.87 | 0.99 | 0.96 | 1.12 | 1.56 | 1.58 | 1.61 | 1.68 |
| — | -36.9% | -12.8% | -7.7% | -22.4% | +22.8% | +10.9% | -2.6% | -19.7% | -25.8% | -30.9% | -23.2% | -22.0% | -44.1% | -37.2% | -40.5% | -33.0% | — | — | — | — | |
| Interest Coverage | 6.31 | 92.00 | 81.00 | 17.43 | 14.50 | 4.08 | 5.13 | 5.92 | 7.77 | 0.90 | -12.44 | 10.25 | 7.78 | -17.10 | 7.20 | 6.80 | -30.88 | 7.75 | 9.29 | 9.00 | 6.57 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 20 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INDV stock.
Indivior Pharmaceuticals Inc's current P/E is 9.8x. The average P/E over the last 4 quarters is 10.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Indivior Pharmaceuticals Inc's current operating margin is 21.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Indivior Pharmaceuticals Inc's business trajectory between earnings reports.